L61H46 shows potent efficacy against human pancreatic cancer through inhibiting STAT3 pathway

References

• SiegelRLMillerKDJemalACancer statistics, 2017CA Cancer J Clin201767173028055103
   PubMed Web of Science ®Google Scholar
• ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
   PubMed Web of Science ®Google Scholar
• XingLShiQZhengKUltrasound-mediated microbubble destruction (UMMD) facilitates the delivery of CA19-9 targeted and paclitaxel loaded mPEG-PLGA-PLL nanoparticles in pancreatic cancerTheranostics20166101573158727446491
   PubMed Web of Science ®Google Scholar
• MahajanUMTellerSSendlerMTumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancerGut201665111838184927196585
   PubMed Web of Science ®Google Scholar
• LeeHJZhuangGCaoYDuPKimHJSettlemanJDrug resistance via feedback activation of Stat3 in oncogene-addicted cancer cellsCancer Cell201426220722125065853
   PubMed Web of Science ®Google Scholar
• ZhaoCLiHLinHJYangSLinJLiangGFeedback activation of STAT3 as a cancer drug-resistance mechanismTrends Pharmacol Sci2016371476126576830
   PubMed Web of Science ®Google Scholar
• YinFHuKChenYSiRNA delivery with PEGylated graphene oxide nanosheets for combined photothermal and genetherapy for pancreatic cancerTheranostics2017751133114828435453
   PubMed Web of Science ®Google Scholar
• YuHPardollDJoveRSTATs in cancer inflammation and immunity: a leading role for STAT3Nat Rev Cancer200991179880919851315
   PubMed Web of Science ®Google Scholar
• YuHLeeHHerrmannABuettnerRJoveRRevisiting STAT3 signalling in cancer: new and unexpected biological functionsNat Rev Cancer2014141173674625342631
   PubMed Web of Science ®Google Scholar
• HerrmannAPricemanSJSwiderskiPCTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cellsJ Clin Invest201512562547
   PubMed Web of Science ®Google Scholar
• JungKHYooWStevensonHLMulti-functional effects of a small-molecule STAT3 inhibitor on NASH and HCC in miceClin Cancer Res201723185537554628533225
   PubMed Web of Science ®Google Scholar
• SahuNChanEChuFCo-targeting of MEK and PDGFR/STAT3 pathways to treat pancreatic ductal adenocarcinomaMol Cancer Ther20171691729173828619758
   PubMed Web of Science ®Google Scholar
• LongKBTookerGTookerEIL-6 receptor blockade enhances chemotherapy efficacy in pancreatic ductal adenocarcinomaMol Cancer Ther20171691898190828611107
   PubMed Web of Science ®Google Scholar
• ZhangZWangFDuCBRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signalingCancer Lett201740221322428602977
   PubMed Web of Science ®Google Scholar
• HuminieckiLHorbanczukJAtanasovAGThe functional genomic studies of curcuminSemin Cancer Biol20174610711828392463
   PubMed Web of Science ®Google Scholar
• NelsonKMDahlinJLBissonJGrahamJPauliGFWaltersMAThe essential medicinal chemistry of curcuminJ Med Chem20176051620163728074653
   PubMed Web of Science ®Google Scholar
• BakerMDeceptive curcumin offers cautionary tale for chemistsNature2017541763614414528079090
   PubMed Web of Science ®Google Scholar
• ZhaoCLiuZLiangGPromising curcumin-based drug design: mono-carbonyl analogues of curcumin (MACs)Curr Pharm Des201319112114213523116317
   PubMed Web of Science ®Google Scholar
• LinLHutzenBZuoMNovel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cellsCancer Res20107062445245420215512
   PubMed Web of Science ®Google Scholar
• WuJPatmoreDMJousmaEEGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumorsOncogene201433217318023318430
   PubMed Web of Science ®Google Scholar
• MaceTAAmeenZCollinsAPancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent mannerCancer Res201373103007301823514705
   PubMed Web of Science ®Google Scholar
• BillMANicholasCMaceTAStructurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell linesPLoS One201278e4072422899991
   PubMed Web of Science ®Google Scholar
• CenLHutzenBBallSNew structural analogues of curcumin exhibit potent growth suppressive activity in human colorectal carcinoma cellsBMC Cancer200999919331692
   PubMed Web of Science ®Google Scholar
• RathKSNaiduSKLataPHO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancerCancer Res20147482316232724590057
   PubMed Web of Science ®Google Scholar
• LiangGShaoLWangYExploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agentsBioorg Med Chem20091762623263119243951
   PubMed Web of Science ®Google Scholar
• TrottOOlsonAJAutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJ Comput Chem201031245546119499576
   PubMed Web of Science ®Google Scholar
• BeckerSGronerBMullerCWThree-dimensional structure of the Stat3beta homodimer bound to DNANature199839466891451519671298
   PubMed Web of Science ®Google Scholar
• SannerMFPython: a programming language for software integration and developmentJ Mol Graph Model1999171576110660911
   PubMed Web of Science ®Google Scholar
• HubbardJMGrotheyANapabucasin: an update on the first-in-class cancer stemness inhibitorDrugs201777101091110328573435
   PubMed Web of Science ®Google Scholar
• AgrawalPFontanals-CireraBSokolovaEA systems biology approach identifies FUT8 as a driver of melanoma metastasisCancer Cell2017316804.e819.e28609658
   PubMed Web of Science ®Google Scholar
• LiuYLiPKLiCLinJInhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cellsJ Biol Chem201028535274292743920562100
   PubMed Web of Science ®Google Scholar
• WuZGabrielsonAHwangJJPhase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancerCancer Chemother Pharmacol20157661309131426507197
   PubMed Web of Science ®Google Scholar
• LiHLiuAZhaoZFragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3)J Med Chem201154155592559621678971
   PubMed Web of Science ®Google Scholar
• LiHMultiple Ligand Simultaneous Docking (MLSD) and Its Applications to Fragment Based Drug Design and Drug Repositioning [Electronic Thesis or Dissertation]Ohio State University2012 Available from: https://etd.ohiolink.edu/Accessed February 6, 2018
   Google Scholar
• YuWLiCZhangWDiscovery of an orally selective inhibitor of signal transducer and activator of transcription 3 using advanced multiple ligand simultaneous dockingJ Med Chem20176072718273128245116
   PubMed Web of Science ®Google Scholar
• VenninCChinVTWarrenSCTransient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasisSci Transl Med20179384eaai850428381539
   PubMed Web of Science ®Google Scholar
• ZengHQuJJinNFeedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancerCancer Cell201630345947327622335
   PubMed Web of Science ®Google Scholar
• ZhangZDuanQZhaoHGemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-kappaB/STAT3 signaling cascadeCancer Lett20163821536327576197
   PubMed Web of Science ®Google Scholar
• JonkerDJNottLYoshinoTA randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trialAnn Oncol201627454O26685010
   PubMed Web of Science ®Google Scholar
• GrotheyATebbuttNVan CutsemECanStem303C trial: a phase III study of BBI-608 (napabucasin) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC)Ann Oncol20163527
   Google Scholar
• BaoGQShenBYPanCPZhangYJShiMMPengCHAndrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancerToxicol Lett20132221233523845849
   PubMed Web of Science ®Google Scholar